

DAFTAR PUSTAKA

- Abrahamson, P. E., Gammon, M. D., Lund, M. J., Flagg, E. W., Porter, P. L., Stevens, J., *et al.*, 2006. General and abdominal obesity and survival among young women with breast cancer. *Cancer Epidemiology and Prevention Biomarkers*. 15 (10):1871-77.
- Adam, J.M.F., 2006. *Obesitas dan Sindrom Metabolik*. Univ. Padjajaran, Bandung.
- Alberti, K. G. M. M., Eckel, R. H., Grundy, S. M., Zimmet, P. Z., Cleeman, J. I., Donato, K. A., *et al.*, 2009. Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; national heart, lung, and blood institute; American heart association; world heart federation; international atherosclerosis society; and international association for the study of obesity. *Circulation*. 120(16):1640-45.
- Alberti, K.G., Zimmet, P.Z., 1998. Definition, diagnosis and classification of diabetes mellitus and its complications. Diagnosis and classification of diabetes mellitus, provisional report of a WHO consultation. *Diabet Med* 15: 539-53
- Alberti, K.G.M.M., Zimmet, P., Shaw, J., 2006. Metabolic syndrome-a new world-wide definition. A Consensus Statement from the International Diabetes Federation. *Diabet Med*. 23: 469-80
- American Cancer Society. 2017. Breast Cancer Risk Factors You Cannot Change. [cited : 2018 May 10]; Available from : <https://www.cancer.org/cancer/breast-cancer/risk-and-prevention/breast-cancer-risk-factors-you-cannot-change.html>.
- Azrad, M., Demark-Wahnefried, W. 2014. The association between adiposity and breast cancer recurrence and survival: a review of the recent literature. *Current nutrition reports*. 3(1), 9-15.
- Berrino, F., Villarini, A., Traina, A., Bonanni, B., Panico, S., Mano, M. P., *et al.*, 2014. Metabolic syndrome and breast cancer prognosis. *Breast Cancer Research and Treatment*. 147 (1):159-65.
- Bhandari, R., Kelley, G. A., Hartley, T. A., Rockett, I. R., 2014. Metabolic syndrome is associated with increased breast cancer risk: a systematic review with meta-analysis. *International journal of breast cancer*. : 18-30
- Cameron, A. J., Shaw, J. E., Zimmet, P. Z., 2004. The metabolic syndrome: Prevalence in worldwide populations. *Endocrinology and Metabolism Clinics of North America*, 33 (2): 351-75.
- Cespedes Feliciano, E. M., 2017. Body mass index, PAM50 subtype, recurrence, and survival among patients with nonmetastatic breast cancer. *Cancer*. 123 (13): 2535-42.

- Cheema, P. K., Burkes, R. L., 2013. Overall survival should be the primary endpoint in clinical trials for advanced non-small-cell lung cancer., *Current oncology (Toronto, Ont.)*. 20(2) : 150-60.
- Cleary, M. P., Grossmann, M. E., 2009. Minireview: Obesity and breast cancer: The estrogen connection. *Endocrinology*. 150 (6): 2537–42.
- Cornier, M., Dabelea, D., Hernandez, T.L., Lindstrom, R.C., Steig, C.J., Stob, N.R., et al., 2008. The Metabolic Syndrome. *Endocrine Reviews*. 29 (7):777–822
- Devang, N., Nandini, M., Adhikari, Prabha. 2016. Mid Arm Circumference: An Alternate Anthropometric Index of Obesity in Type 2 Diabetes and Metabolic Syndrome, *British Journal of Medicine and Medical Research*. 12 (1): 1–8.
- Dignam, J. J., Wieand, K., Johnson, K. A., Fisher, B., Xu, L., Mamounas, E. P., et al., 2003. Obesity, tamoxifen use, and outcomes in women with estrogen receptor–positive early-stage breast cancer. *Journal of the National Cancer Institute*, 95 (19): 1467-76.
- Dong, G., Wang, D., Liang, X., Gao, H., Wang, L., Yu, X., et al., 2014. Factors related to survival rates for breast cancer patients. *International Journal of Clinical and Experimental Medicine*. 7 (10): 3719–24.
- Edge SB., Compton CC., 2010. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. *Ann Surg Oncol*.17 (6) :1471-4.
- Einhorn, D., Reaven, G.M., Cobin, R.H., Ford, E., Ganda, O.P., Handelsman., 2003. American College of Endocrinology position statement on the insulin resistance syndrome. *Endocr Pract* 9: 237-52
- Ellis, E.O., Schnitt, S.J., Sastre-Garau, X., Bussolati, G., Tavassoli, F. A., Eusebi, V., 2003. The breast. In Tavasolli, D., (Ed.). *Pathology and genetic of tumours of the breast and female genital organs / WHO classification of tumours*, pp: 34 – 6, IARC Press, Washington.
- Fryzek, J. P., Poulsen, A. H., Lipworth, L., Pedersen, L., Nørgaard, M., McLaughlin, J. K., et al., 2006. A cohort study of antihypertensive medication use and breast cancer among Danish women. *Breast cancer research and treatment*. 97 (3): 231-36.
- Furberg, A. S., Veierød, M. B., Wilsgaard, T., Bernstein, L., Thune, I., 2004. Serum high-density lipoprotein cholesterol, metabolic profile, and breast cancer risk. *Journal of the National Cancer Institute*. 96 (15): 1152-60.
- Ganz, P. A., Habel, L. A., Weltzien, E. K., Caan, B. J., Cole, S. W., 2011. Examining the influence of beta blockers and ACE inhibitors on the risk for breast cancer recurrence: results from the LACE cohort. *Breast cancer research and treatment*. 129 (2): 549.
- Goodwin, P. J., Stambolic, V., 2015. Impact of the Obesity Epidemic on Cancer. *Annual Review of Medicine*. 66 (1): 281–96.

- Grundy, M.S., 2016 Metabolic Syndrome update. *Trends in Cardiovascular Medicine* 26:364-73
- Heath, J., 2014. *A Comparison of Anthropometric Measures for Classification of Metabolic Syndrome and Cardiometabolic Risk Factors, NHANES 2007-2010* [thesis]. Georgia State University, Georgia.
- Hennigs, A., Riedel, F., Gondos, A., Sinn, P., Schirmacher, P., Marmé, F., *et al.*, 2016. Prognosis of breast cancer molecular subtypes in routine clinical care: A large prospective cohort study. *BMC cancer* 16 : 734.
- Hong, S., Didwania, A., Olopade, O., Ganschow, P., 2009. The expanding use of third-generation aromatase inhibitors: what the general internist needs to know. *Journal of general internal medicine*. 24 (2): 383-88.
- Hudson, J. I., Pope, H. G., Glynn, R. J., 2005. The cross-sectional cohort study: An underutilized design. *Epidemiology*, 16 (3):355–59
- IDF, 2006. The IDF consensus worldwide definition of the metabolic syndrome. *International Diabetes Federation* [cited 2017 Oct 28]. Available from: <https://www.idf.org/component/attachments/attachments.html?id=705&task=download>
- International Agency for Research on Cancer (IARC) / WHO*, 2012. *GLOBOCAN 2012: Estimated cancer incidence, mortality, and prevalence worldwide in 2012* [cited 2018 May 20]. Available from: http://globocan.iarc.fr/Pages/fact_sheets_population.aspx
- International Society for the Advancement of Kinanthropometry (ISAK), 2001. International Standards for Anthropometric Assessment [cited 2018 May 20]. Available from : <http://www.ceap.br/material/MAT17032011184632.pdf>
- James, P. A., Oparil, S., Carter, B. L., Cushman, W. C., Dennison-Himmelfarb, C., Handler, J., 2014. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). *Jama*. 311(5): 507-20.
- Jayawardena, R., Punchihewa, P., Chinthanie, S., Lokunarangoda, N., Pathirana, A. K. 2017. The use of mid upper arm circumference and skinfold thickness to assess underweight and obesity among cardiac patients. *Sri Lanka Journal of Diabetes Endocrinology and Metabolism*. 7 (2)
- Jeon, Y. W., Kang, S. H., Park, M. H., Lim, W., Cho, S. H., Suh, Y. J., 2015. Relationship between body mass index and the expression of hormone receptors or human epidermal growth factor receptor 2 with respect to breast cancer survival. *BMC cancer*. 15(1): 865.
- Jiralerspong, S., Goodwin, P. J., 2016. Obesity and breast cancer prognosis: evidence, challenges, and opportunities. *Journal of Clinical Oncology*. 34 (35): 4203-16.

- Jiralerspong, S., Kim, E. S., Dong, W., Feng, L., Hortobagyi, G. N., Giordano, S. H., 2013. Obesity, diabetes, and survival outcomes in a large cohort of early-stage breast cancer patients. *Annals of oncology*. 24 (10): 2506-14.
- Johnsen, S. P., Jacobsen, J., Monster, T. B., Friis, S., McLaughlin, J. K., Sørensen, H. T., 2005. Risk of first-time hospitalization for angioedema among users of ACE inhibitors and angiotensin receptor antagonists. *The American journal of medicine*. 118 (12): 1428-29.
- Kamineni, A., Anderson, M. L., White, E., Taplin, S. H., Porter, P., Ballard-Barbash, R., 2013. Body mass index, tumor characteristics, and prognosis following diagnosis of early-stage breast cancer in a mammographically screened population. *Cancer Causes & Control*. 24 (2): 305-12.
- Kawai, M., Tomotaki, A., Miyata, H., Iwamoto, T., Niikura, N., Anan., 2016. Body mass index and survival after diagnosis of invasive breast cancer: a study based on the Japanese National Clinical Database—Breast Cancer Registry. *Cancer medicine*. 5 (6): 1328-40.
- Kelsey, J.L., Whittemore, A.S., Evans, A.S., Thompson, W.D., 1996. *Methods in Observational Epidemiology*. Oxford University Press, Oxford.
- Kementerian Kesehatan RI, 2013. Riset Kesehatan Dasar (RISKESDAS). Badan Litbang Kemenkes RI, Jakarta.
- Kemp, A., Preen, D. B., Saunders, C., Boyle, F., Bulsara, M., Holman, C. A. J., 2014. Women commencing anastrozole, letrozole or tamoxifen for early breast cancer: the impact of comorbidity and demographics on initial choice. *PloS one*. 9 (1): e84835.
- Khambri, D. 2015. Peran terapi endokrin pada kanker payudara. *Maj. Kedokt. Andalas*. 38 (1): 64-73.
- Knüpfer, H., Preiß, R., 2007. Significance of interleukin-6 (IL-6) in breast cancer. *Breast cancer research and treatment*. 102 (2): 129-35.
- Komite Nasional Penanggulangan Kanker (KPKN). 2017. Panduan Nasional Penanganan Kanker Payudara. Kementerian Kesehatan Republik Indonesia, Jakarta.
- Kumar, N. B., Cantor, A., Allen, K., Cox, C. E., 2000. Android obesity at diagnosis and breast carcinoma survival: evaluation of the effects of anthropometric variables at diagnosis, including body composition and body fat distribution and weight gain during life span, and survival from breast carcinoma. *Cancer*. 88 (12): 2751-57.
- Kwan, M. L., John, E. M., Caan, B. J., Lee, V. S., Bernstein, L., Cheng, I., 2014. Obesity and mortality after breast cancer by race/ethnicity: The California Breast Cancer Survivorship Consortium. *American journal of epidemiology*. 179 (1): 95-111.

- Lauring, J., Wolff, A.C., 2016. Evolving Role of the Estrogen Receptor as a Predictive Biomarker: ESR1 Mutational Status and Endocrine Resistance in Breast Cancer. *J Clin Oncol.* 34 (25):2950-2.
- Lumachi, F., Brunello, A., Maruzzo, M., Basso, U., & Mm Basso, S. 2013. Treatment of estrogen receptor-positive breast cancer. *Current medicinal chemistry.* 20 (5): 596-604.
- Nagrani, R., Mhatre, S., Rajaraman, P., Soerjomataram, I., Boffetta, P., Gupta, S., 2016. Central obesity increases risk of breast cancer irrespective of menopausal and hormonal receptor status in women of South Asian Ethnicity. *European Journal of Cancer* 66: 153–161.
- NCEP, 2002. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. *Circulation.* 3143-421.
- Nugraha, D.R., 2019. *Hubungan penambahan berat badan selama terapi hormonal terhadap kekambuhan pada pasien kanker payudara subtipe reseptor estrogen positif her2 negatif* [tesis]. Univ. Gadjah Mada, Yogyakarta
- Osborne, B. C. K., Zhao, H. H., Fuqua, S. A. W., 2016. Selective Estrogen Receptor Modulators : Structure , Function , and Clinical Use. *J Clin Oncol.* 18 (17) :3172-86
- PERKENI .2015. Konsensus Pengelolaan dan Pencegahan Diabetes Mellitus tipe 2 di Indonesia. PB PERKENI, Jakarta.
- Pfeiler, G., Stöger, H., Dubsy, P., Mlineritsch, B., Singer, C., Balic, M., 2013. Efficacy of tamoxifen±aminoglutethimide in normal weight and overweight postmenopausal patients with hormone receptor-positive breast cancer: an analysis of 1509 patients of the ABCSG-06 trial. *British journal of cancer,* 108 (7): 1408-1414.
- Saad, E. D., Katz, A., 2009. Progression-free survival and time to progression as primary end points in advanced breast cancer: Often used, sometimes loosely defined. *Annals of Oncology.* 20 (3): 460–64.
- Sagun, G., Oguz, A., Karagoz, E., Filizer, A. T., Tamer, G., Mesci, B., 2014. Application of alternative anthropometric measurements to predict metabolic syndrome. *Clinics,* 69 (5): 347-53.
- Scheen, A.J., 2004. Combined thiazolidinedione-insulin therapy: should we be concerned about safety? *Drug saf.* 27 (12): 841-56
- Scheid, M. P., Sweeney., G. 2014. The role of adiponectin signaling in metabolic syndrome and cancer. *Reviews in Endocrine and Metabolic Disorders.* 15 (2): 157-67.
- Senkus, E., Kyriakides, S., Ohno, S., Penault-Llorca, F., Poortmans, P., Rutgers, E.,. 2015. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Annals of oncology.* 26 (5 Suppl), 8S-30S

- Sestak, I., Distler, W., Forbes, J. F., Dowsett, M., Howell, A., & Cuzick, J. 2010. Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial. *Journal of Clinical Oncology*, 28(21): 3411-5.
- Sestak, I., Howell, A., Harvie, MN., Forbes, JF., 2012. Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with or at high risk of developing breast cancer. *Breast Cancer Research and Treatment*. 134 (2): 727–34.
- Shen, W., Punyanitya, M., Chen, J., Gallagher, D., Albu, J., Pi-Sunyer, X., Heymsfield, S. B., 2006. Waist circumference correlates with metabolic syndrome indicators better than percentage fat. *Obesity*, 14 (4): 727-736.
- Socialstyrelsen. 2006 .*Cancer Incidence in sweden 2004* [cited 2018 Jun 10]. Available from : URL:www.socialstyrelsen.se/statistik/statistik_amne/cancer.
- Stebbing, J., Sharma, A., North, B., Athersuch, T. J., Zebrowski, A., Keun, H. C., 2011. A metabolic phenotyping approach to understanding relationships between metabolic syndrome and breast tumour responses to chemotherapy. *Annals of Oncology*. 23(4): 860-6.
- Suhaema., Masthalina, H., 2015. Pola Konsumsi Dengan Terjadinya Sindrom Metabolik di Indonesia. *Jurnal Kesehatan Masyarakat Nasional*. 9 (4): 340–47.
- Sun, X., Nichols, H. B., Robinson, W., Sherman, M. E., Olshan, A. F., Troester, M. A., 2015. Post-diagnosis adiposity and survival among breast cancer patients: influence of breast cancer subtype. *Cancer Causes & Control*. 26(12): 1803-11.
- Thaker, P. H., Han, L. Y., Kamat, A. A., Arevalo, J. M., Takahashi, R., Merritt, W. M., 2006. Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. *Nature medicine*. 12 (8): 939-44.
- Tim Cancer Helps, 2010. *Stop Kanker*. PT. Agro Media Pustaka, Jakarta.
- Tota-Maharaja, R., Defilippisa, A.P., Blumenthala, R.S., Blaha, M.J., 2010. A practical approach to the metabolic syndrome: review of current concepts and management. *Current Opinion in Cardiology* 25:502–12
- Trisnawati, Ika., 2008. *Kadar Adiponektin Pada Orang Obes Dengan dan Tanpa Dislipidemia Aterogenik* [thesis]. Univ. Gadjah Mada, Yogyakarta.
- Vasan, S. K., Thomas, N., Christopher, S., Geethanjali, F. S., Paul, T. V., Sanjeevi, C. B. 2011. Anthropometric measurements for the prediction of the metabolic syndrome: a cross-sectional study on adolescents and young adults from southern india. *Heart Asia*. 3(1), 2-7
- Widschwendter, P., Friedl, T., Schwentner, L, DeGregorio, N., 2015. The influence of obesity on survival in early, high-risk breast cancer: Results from the randomized SUCCESS A trial. *Breast Cancer Research*. 17 (1): 1–11.

- Wisse, A., Tryggvadottir, H., Simonsson, M., Isaksson, K., Rose, C., Jernström, H. 2018. Increasing preoperative body size in breast cancer patients between 2002 and 2016: implications for prognosis. *Cancer Causes & Control*, 29 (7): 643-56.
- World Health Organization (WHO)., 1996. *WHO Technical Report Series Geneva*. WHO Press, Geneva.
- World Health Organization (WHO)., 2000. *The Asia-Pacific perspective: redefining obesity and its treatment* [cited 2018 Nov 2]. Available from :http://apps.who.int/iris/bitstream/handle/10665/206936/0957708211_eng.pdf?sequence=1
- World Health Organization (WHO)., 2004. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. *Lancet*. 363 (9403) :157–63
- World Health Organization (WHO)., 2008. *Waist Circumference and Waist-Hip Ratio, Report of a WHO Expert Consultation*. WHO Press, Geneva.
- Yu, M., Zhou, X., Niu, L., Lin, G., Huang, J., Zhou, W., Li, Z., 2013. Targeting transmembrane TNF- α suppresses breast cancer growth. *Cancer research*. 73 (13): 4061-74